If you are an Accredited Investor and are interested in learning more about investment opportunities with Soricimed Biopharma, please contact us.
Orphan Drug Designation
FDA orphan drug status for ovarian and pancreatic cancer.
Broad Patent Protection
Broad international patent protection including composition of matter and method claims.
Efficient Business Model
Semi-virtual business model resulting in extremely capital efficient operation.
We are seeking additional capital to continue our clinical development of SOR-C13 and advance our Peptide-Drug Conjugate program.
To date, we have been financed by high net worth individuals and angel investors.
If you would like to learn more about the investment potential of Soricimed Biopharma Inc., please fill out the form at the top of the page.